A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation

por Marshall, Jason D., Heeke, Darren S., Rao, Eileen, Maynard, Sean K., Hornigold, David, McCrae, Christopher, Fraser, Neil, Tovchigrechko, Andrey, Yu, Li, Williams, Nicola, King, Sarah, Cooper, Martin E., Hajjar, Adeline M., Woo, Jennifer C.
Publicado 2016

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

por Jain, Michael D., Miklos, David B., Jacobson, Caron A., Timmerman, John M., Sun, Jennifer, Nater, Jenny, Fang, Xiang, Patel, Ankit, Davis, Madison, Heeke, Darren, Trinh, Tan, Mattie, Mike, Neumann, Frank, Kim, Jenny J., To, Christina, Filosto, Simone, Reshef, Ran
Publicado 2023

Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses

por Romain, Gabrielle, Strati, Paolo, Rezvan, Ali, Fathi, Mohsen, Bandey, Irfan N., Adolacion, Jay R T., Heeke, Darren, Liadi, Ivan, Marques-Piubelli, Mario L., Solis, Luisa M., Mahendra, Ankit, Vega, Francisco, Cooper, Laurence J.N., Singh, Harjeet, Mattie, Mike, Bot, Adrian, Neelapu, Sattva S., Varadarajan, Navin
Publicado 2022